Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:07:12 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



News for U:RGLS from 2023-05-04 to 2024-05-03 - 22 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-30 08:00U:RGLSNews ReleaseRegulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
2024-03-21 16:05U:RGLSNews ReleaseRegulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
2024-03-12 06:32U:RGLSNews ReleaseRegulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
2024-03-12 06:30U:RGLSNews ReleaseRegulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2024-01-02 16:05U:RGLSNews ReleaseRegulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2023-11-22 08:00U:RGLSNews ReleaseRegulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
2023-11-09 16:05U:RGLSNews ReleaseRegulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
2023-11-02 08:00U:RGLSNews ReleaseRegulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2023-10-19 08:00U:RGLSNews ReleaseRegulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2023-09-20 07:00U:RGLSNews ReleaseRegulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2023-09-13 08:00U:RGLSNews ReleaseRegulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2023-09-05 08:00U:RGLSNews ReleaseRegulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
2023-08-23 08:00U:RGLSNews ReleaseRegulus Therapeutics to Host Virtual Investor Event on September 6, 2023
2023-08-08 16:05U:RGLSNews ReleaseRegulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
2023-08-02 08:00U:RGLSNews ReleaseRegulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
2023-07-18 08:00U:RGLSNews ReleaseRegulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
2023-06-27 08:00U:RGLSNews ReleaseRegulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2023-06-23 08:00U:RGLSNews ReleaseRegulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
2023-06-20 08:00U:RGLSNews ReleaseRegulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital
2023-06-12 08:00U:RGLSNews ReleaseRegulus Therapeutics Strengthens Research & Development Leadership
2023-05-16 08:00U:RGLSNews ReleaseRegulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2023-05-11 16:05U:RGLSNews ReleaseRegulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates